Several studies have shown that anti-EpCAM antibodies limit therapeutic efficacies as the results of showing dose- and target-dependent in metastatic cancers, short serum half-life, altered EpCAM expression pattern, and differential cleavage and localization of EpICD in cancer cells (Fig. 3) [143, 144]. This evidence concerns the gene EPCAM and cancer.